GNNSF
Genscript Biotech Corporation
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Strong buy
+75/100
Last price
6.35
▲ 0.55 (9.48%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
5.80
Day high
5.83
Day low
5.70
Volume
3.00K
Market cap
$14.48B
P/E (TTM)
—
52W range
1.30 – 6.55
Trailing performance
Returnvs SPY
1W
+18.69%
+16.7%
1M
+58.75%
+57.6%
3M
+296.87%
+292.4%
6M
+347.18%
+329.0%
YTD
+281.38%
+267.1%
1Y
+182.22%
+165.8%
3Y
+140.90%
+58.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on GNNSF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
769.56M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 2, 26 | Shao (Weihui) Chief Executive Officer |
SELL | 155.53K | $708.96K | Direct |
| Sep 2, 26 | Zhu (Li) Director (Executive) |
SELL | 1.74K | $7.92K | Direct |
| Sep 1, 26 | Zhu (Li) Director (Executive) |
SELL | 32.88K | $150.70K | Direct |
| Aug 20, 26 | Zhu (Li) Director (Executive) |
SELL | 34.00K | $143.86K | Direct |
| Aug 18, 26 | Zhu (Li) Director (Executive) |
SELL | 98.08K | $326.20K | Direct |
| Jun 8, 26 | Shao (Weihui) Chief Executive Officer |
SELL | 313.65K | $485.09K | Direct |
| Jun 8, 26 | Zhu (Li) Director (Executive) |
SELL | 3.03K | $4.68K | Direct |
| Jun 4, 26 | Shao (Weihui) Chief Executive Officer |
— | 628.87K | — | Direct |
| Jun 4, 26 | Zhu (Li) Director (Executive) |
— | 20.00K | — | Direct |
| Apr 2, 26 | Shao (Weihui) Chief Executive Officer |
— | 52.78K | — | Direct |
| Dec 31, 25 | Meng (Jiange) Chairman of the Board |
— | 80.00K | — | Direct |
| Dec 31, 25 | Meng (Jiange) Chairman of the Board |
SELL | 41.91K | $66.65K | Direct |
| Dec 31, 25 | Pan (Jiuan) Independent Non-Executive Director |
— | 5.48K | — | Direct |
| Dec 31, 25 | Zhu (Li) Director (Executive) |
— | 40.00K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
Dai (Zumian) |
Independent Non-Executive Director | 36.62K | Other |
Grossman (Ross Allen) |
Independent Non-Executive Director | 6.54K | Other |
Meng (Jiange) |
Chairman of the Board | 400.70K | Conversion |
Pan (Jiuan) |
Independent Non-Executive Director | 14.93K | Other |
Quelch (John Anthony) |
Independent Non-Executive Director | 6.57K | Conversion |
Shao (Weihui) |
Chief Executive Officer | 1.43M | Sale |
Wang (Ye) |
President | 5.93M | Conversion |
Zhu (Li) |
Director (Executive) | 909.93K | Sale |
Fundamentals
Market cap$14.48B
Enterprise value$12.22B
Revenue (TTM)$844.97M
Gross profit$439.28M
EBITDA$192.65M
Net income$-636.71M
EPS (TTM)$-0.29
Free cash flow$94.85M
Total cash$810.27M
Total debt$343.53M
Book value / share$1.78
Shares outstanding2.28B
Float1.41B
Short % of float—
Dividend yield0.00%
Beta (5Y)0.81
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book3.57
EV / revenue14.47
EV / EBITDA63.45
Gross margin51.99%
Operating margin12.26%
Profit margin-75.35%
Return on equity-15.33%
Return on assets1.54%
Debt / equity8.82
Current ratio1.53
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $959.53M | $594.49M | $560.48M | $625.70M | +61.4% |
| Operating revenue | $959.53M | $594.49M | $560.48M | $625.70M | +61.4% |
| Cost of revenue | $406.32M | $322.36M | $289.85M | $321.62M | +26.0% |
| Gross profit | $553.20M | $272.13M | $270.63M | $304.08M | +103.3% |
| Research & development | $71.23M | $53.79M | $52.70M | $390.10M | +32.4% |
| Selling, general & admin | $228.06M | $202.50M | $186.96M | $350.81M | +12.6% |
| Total operating expense | $291.07M | $249.41M | $230.44M | $731.84M | +16.7% |
| Operating income | $262.13M | $22.71M | $40.18M | -$427.76M | +1,054.1% |
| Net interest income | $8.81M | $21.35M | $16.84M | -$51.00K | -58.7% |
| Pre-tax income | -$470.53M | -$170.80M | $168.88M | -$431.69M | -175.5% |
| Tax provision | $61.87M | $2.98M | $6.01M | -$3.72M | +1,978.3% |
| Net income | -$532.83M | $2.96B | -$95.48M | -$226.85M | -118.0% |
| Net income to common | -$532.83M | $2.96B | -$95.48M | -$226.85M | -118.0% |
| Basic EPS | -0.25 | 1.40 | -0.05 | -0.11 | -117.6% |
| Diluted EPS | -0.25 | 1.36 | -0.05 | -0.11 | -118.1% |
| EBIT | -$453.24M | -$162.76M | $174.62M | -$418.42M | -178.5% |
| EBITDA | -$379.20M | -$85.09M | $248.67M | -$354.17M | -345.6% |
| Basic shares | 2.17B | 2.12B | 2.11B | 2.10B | +2.2% |
| Diluted shares | 2.19B | 2.18B | 2.20B | 2.10B | +0.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $142.49M | $131.99M | $1.45B | $1.02B | +8.0% |
| Cash & short-term investments | $811.99M | $621.18M | $1.93B | $1.46B | +30.7% |
| Accounts receivable | $130.22M | $109.89M | $211.10M | $96.93M | +18.5% |
| Inventory | $39.59M | $31.10M | $53.35M | $59.94M | +27.3% |
| Total current assets | $1.08B | $834.98M | $2.35B | $1.76B | +29.2% |
| Property, plant & equipment | $623.27M | $602.84M | $750.95M | $646.92M | +3.4% |
| Goodwill & intangibles | $14.62M | $14.37M | $20.00M | $26.36M | +1.7% |
| Total assets | $4.85B | $5.28B | $3.39B | $2.55B | -8.1% |
| Total current liabilities | $720.17M | $781.07M | $494.81M | $545.98M | -7.8% |
| Current debt | $194.67M | $88.75M | $57.01M | $33.68M | +119.4% |
| Long-term debt | $0 | $17.31M | $287.21M | $261.01M | -100.0% |
| Total debt | $258.84M | $170.57M | $416.99M | $349.80M | +51.8% |
| Total liabilities | $888.59M | $954.91M | $1.34B | $1.18B | -6.9% |
| Retained earnings | $1.82B | $2.35B | -$611.51M | -$516.04M | -22.7% |
| Shareholder equity | $3.96B | $4.32B | $1.39B | $1.01B | -8.4% |
| Working capital | $358.80M | $53.90M | $1.86B | $1.22B | +565.6% |
| Net tangible assets | $3.94B | $4.31B | $1.37B | $984.18M | -8.4% |
| Shares issued | 2.18B | 2.14B | 2.12B | 2.11B | +1.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$470.53M | $2.86B | -$350.98M | -$431.69M | — | -116.4% |
| Depreciation & amortisation | $74.04M | $77.67M | $74.05M | $64.25M | — | -4.7% |
| Stock-based compensation | $14.79M | $76.52M | $60.59M | $65.15M | — | -80.7% |
| Change in working capital | -$1.82M | $85.44M | -$86.91M | $164.47M | — | -102.1% |
| Operating cash flow | $325.52M | $75.65M | -$286.91M | -$120.29M | — | +330.3% |
| Capital expenditure | -$83.84M | -$147.92M | -$157.71M | -$203.57M | — | +43.3% |
| Investing cash flow | -$171.95M | -$1.46B | -$357.73M | -$443.30M | — | +88.2% |
| Share buybacks | -$225.14M | $0 | — | — | $0 | — |
| Financing cash flow | -$144.89M | $66.52M | $1.07B | $419.32M | — | -317.8% |
| Free cash flow | $241.69M | -$72.27M | -$444.62M | -$323.86M | — | +434.4% |
| End cash position | $142.49M | $131.99M | $1.45B | $1.02B | — | +8.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2025-12-31 | 2025-06-30 | YoY |
|---|---|---|---|
| Cash & equivalents | $142.49M | $293.21M | -51.4% |
| Cash & short-term investments | $811.99M | $938.36M | -13.5% |
| Accounts receivable | $130.22M | $126.48M | +3.0% |
| Inventory | $39.59M | $38.80M | +2.0% |
| Total current assets | $1.08B | $1.18B | -8.3% |
| Property, plant & equipment | $623.27M | $606.31M | +2.8% |
| Goodwill & intangibles | $14.62M | $14.11M | +3.6% |
| Total assets | $4.85B | $5.43B | -10.7% |
| Total current liabilities | $720.17M | $600.53M | +19.9% |
| Current debt | $194.67M | $155.46M | +25.2% |
| Long-term debt | $0 | $0 | — |
| Total debt | $258.84M | $218.63M | +18.4% |
| Total liabilities | $888.59M | $1.01B | -12.3% |
| Retained earnings | $1.82B | $2.32B | -21.8% |
| Shareholder equity | $3.96B | $4.42B | -10.3% |
| Working capital | $358.80M | $576.28M | -37.7% |
| Net tangible assets | $3.94B | $4.40B | -10.4% |
| Shares issued | 2.18B | 2.18B | +0.2% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $889.41M | -7.3% |
| Next year | — | — | $1.07B | +20.8% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders35.19%
Held by institutions29.99%
Institutions holding194
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
5.53
+14.73% from price
SMA 20
5.00
+26.92% from price
SMA 50
4.01
+58.22% from price
SMA 100
2.83
+124.32% from price
SMA 200
2.24
+183.17% from price
EMA 12
5.47
+15.99% from price
EMA 26
4.93
+28.87% from price
EMA 50
4.20
+51.05% from price
RSI (14)
76.5
Overbought
MACD (12,26,9)
0.55
Hist 0.05
ATR (14)
0.32
5.04% of price
Realised vol 30D
102.9%
Annualised
Bollinger upper
6.48
20, 2σ
Bollinger lower
3.53
20, 2σ
50 / 200 cross
Golden
4.01 vs 2.24
Trend bias
Above 200
+183.17%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.14
Less volatile than market
Correlation to SPY
-0.02
Largely independent
Realised vol 30D
102.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-44.1%
Peak to trough
Max drawdown 5Y
-79.6%
Peak to trough
ATR 14
0.32
5.04% of price
Beta (reported)
0.81
5Y monthly, from filing
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend dateJun 5, 2017
Next pay date—
Last split—
Split date—
Headlines
Recombinant Proteins Market - Global Strategic Business Report: Sales Hit to $5.8 Billion by 2030 - Benchmark Thermo Fisher Scientific, Merck KGaA, Amgen, Bio-Techne and GenScript Biotech Amid Tariff Disruption
GlobeNewswire · 7d ago
Global DNA Manufacturing Market Size, Share, Trends, and Forecast, 2026-2033 | Market to Reach $23.1 Billion as Gene Therapy and Synthetic Biology Drive 17.8% CAGR
GlobeNewswire · 9d ago
DNA Synthesis Market Outlook 2026-2035 - Featuring Profiles of Leading Companies Integrated DNA Technologies, GenScript Biotech, and Twist Bioscience
GlobeNewswire · 20d ago
ProBio and Kun Tuo Announce Strategic Collaboration to Deliver Integrated CDMO-CRO Solutions for Advanced Therapies
PR Newswire · 21d ago
GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles
PR Newswire · 50d ago
GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles
PR Newswire · 50d ago
Genscript Biotech Corp (GNNSF) (H1 2026) Earnings Call Highlights: Revenue Surges 27.3% to $404. ...
GuruFocus.com · 52d ago
GenScript and Tamarind Bio Partner to Connect AI Molecular Design with Rapid Lab Validation
PR Newswire · 63d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.